10 seconds cooling anesthesia for painless
intravitreal injection in 1 minute
What is intravitreal injection (IVI)?

Intravitreal injection (IVI) is the most common in-office procedure performed by retina specialists, with over 6 million injections performed each year in the United Sates. IVI is used to administer medication into the vitreous cavity to treat various retinal conditions such as age-related macular
degeneration (nAMD), diabetic retinopathy and retinal vein occlusions.

Anesthetizing the eye before IVI

Before IVI can be administered, several anesthetic methods such as topical anesthesia drops, gel and subconjunctival injection are being used
by retina specialists. Each of this anesthesia has its own limitations such as long onset of action, post-IVI soreness, subconjunctival hemorrhage, or suboptimal anesthetic effect.

Ocular Cooling Anesthesia

Recens Medical’s ocular cooling anesthesia based on precision tissue cooling technology is designed to make IVI a rapid and painless procedure.
Cold temperatures are known to significantly suppress neuronal signal transmission. Our ocular cooling anesthesia provides such cold temperatures with utmost precision to anesthetize patient’s eye at an unprecedented speed and safety. In 10 seconds, sufficient anesthesia is achieved for a painless IVI, enabling anesthesia and injection within a single visit. Recens Medical’s ocular cooling anesthesia is the first-of-kind non-pharmacologic
anesthesia that greatly reduces time exposure of patient’s eye to topical anesthesia, and therefore minimizes complications resulting
from pharmacological anesthesia.

Clinical program

The efficacy and long term safety of ocular cooling anesthesia have been demonstrated with the pilot trial COOL-1 (clinicaltrials.gov: NCT03732287) and ongoing multi-site trial COOL-2 (clinicaltrials.gov: NCT03956797).


    Perform injection immediately after cooling anesthesia and complete the whole IVI procedure within a single visit

    Provide better and more comfortable IVI experience for patients than pharmacological anesthesia
  • SAFE

    Reduced exposure to pharmacological anesthesia leads to better post-injection recovery

*The ocular cooling anesthesia device is pending for FDA approval.